ECP Workshop - The Patients’ Journey Around Immunomodulation and Rejection

Around 25% of organ transplant recipients encounter acute rejection within the initial year post-transplantation. Acute rejection is further categorized into cellular (ACR) and antibody-mediated (AMR) forms. Over the long term, the threat shifts to chronic rejection, posing a risk to patient survival even with immunosuppressive drug treatments. Factors such as opportunistic viral infections and malignancies contribute to this risk. Consequently, there is a keen interest in therapies that can effectively modulate the immune system, presenting promising avenues for treating and preventing rejection in transplant recipients.

This workshop explores the patient experience of immunomodulation and rejection, focusing on how patients and their families perceive and emotionally respond to rejection.

Target Audience: 

Patients, Caregivers, Patient Advocates, Representatives of Patient Associations and Organizations

Workshop creators: 

Markus Johannes Barten (Germany)

Julie Guest (UK)

Invited speakers and moderators:

Francis Ayuketang Ayuk (Germany)

Markus Johannes Barten (Germany)

Charlotte Davies (UK)

Pisana Ferrari (Italy)

Julie Guest (UK)

Marc Kritzky (Germany)